Phase I/II Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Trial Profile

Phase I/II Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Jun 2017

At a glance

  • Drugs Nivolumab (Primary) ; Cytarabine; Dexamethasone; Idarubicin; Methylprednisolone
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Jun 2017 Planned End Date changed from 1 Jul 2018 to 1 Jul 2019.
    • 14 Jun 2017 Planned primary completion date changed from 1 Jul 2018 to 1 Jul 2019.
    • 20 Jul 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top